Head-To-Head Contrast: Rennova Health (OTCMKTS:RNVA) vs. MDxHealth (NASDAQ:MDXH)

Rennova Health (OTCMKTS:RNVA) and MDxHealth (NASDAQ:MDXH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Rennova Health and MDxHealth, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rennova Health	0	0	0	0	0.00
MDxHealth	1	0	4	0	2.60

MDxHealth has a consensus target price of $7.75, indicating a potential upside of 113.50%. Given MDxHealth’s stronger consensus rating and higher probable upside, analysts clearly believe MDxHealth is more favorable than Rennova Health.

Risk & Volatility

Rennova Health has a beta of 22.39, indicating that its stock price is 2,139% more volatile than the S&P 500. Comparatively, MDxHealth has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500.

Profitability

This table compares Rennova Health and MDxHealth’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rennova Health	N/A	N/A	N/A
MDxHealth	-30.50%	-1,078.01%	-20.05%

Earnings and Valuation

This table compares Rennova Health and MDxHealth”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rennova Health	$18.69 million	0.00	-$7.73 million	N/A	N/A
MDxHealth	$90.05 million	1.91	-$38.07 million	($0.64)	-5.67

Rennova Health has higher earnings, but lower revenue than MDxHealth.

Summary

Rennova Health beats MDxHealth on 5 of the 9 factors compared between the two stocks.

About Rennova Health

Rennova Health, Inc., together with its subsidiaries, provides health care services in the United States. It owns one operating hospital in Oneida, Tennessee; and a rural clinic in Williamsburg, Kentucky. The company is based in West Palm Beach, Florida.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.